Background: GATA-3 is a potential marker for detection of metastatic breast carcinoma, reportedly more sensitive than mammaglobin (MAM) and GCDFP-15. We aim to compare the sensitivity of GATA-3, MAM and GCDFP-15 in determining the breast origin of malignant effusions. Methods: Cell blocks from 27 cases of serous effusions positive for metastatic breast cancer were retrieved. Immunohistochemistry for GATA-3, MAM, gross cystic disease fluid protein 15 (GCDFP-15), estrogen receptor (ER) and progesterone receptor (PR) was performed on cell-block micro-array. Statistical analysis using two ways Chi square, one-way ANOVA and multiple regression was performed. Results: The detection rate of breast cancer in serous fluid was significantly higher with GATA-3 (88.8 %, X2 = 15.9, p = 0.00034) than with MAM (51.8 %) and GCDFP-15 (37.0 %). All ER positive cases (19) were GATA-3 positive. Conversely, all GATA-3 negative cases (3) were ER negative. The intensity of stain and percentage of positive cells were significantly higher with GATA-3 (p < 0.0001) than with MAM and GCDFP-15. The intensity and percentage of positive cells score of GATA-3 were statistically associated with ER stain intensity and percentage of positive cell scores.
Introduction
GATA binding protein 3 is one of six members of the GATA family of zinc finger transcription factors that recognize a specific nucleotide sequence in the promoter region of target genes [1] . GATA-related genes are involved in complex regulatory pathways and in the development of mammary glands and thymocytes [2, 3] . More specifically, GATA-3 plays an essential role in regulating mammary-gland morphogenesis and luminal cell differentiation and has been identified to play an important role in tumor initiation [3, 4] . GATA-3 has recently been identified as a multi-specific but successful immunohistochemical marker for breast and urothelial differentiation [5, 6] . It is also expressed in a subset squamous cell carcinomas, salivary gland tumors, mesotheliomas, gynecologic carcinomas and skin adnexal tumors [5, 7, 8] . In spite of its multi-specific nature, GATA-3 was recently reported to have high positive predicitve value (96.2 %) in determining the breast origin in serous malignant effusion [9] . GATA-3 and estrogen receptor (ER) are involved in a cross-regulatory loop that explains initial reports correlating GATA-3 expression to ER expression; however, recent data support that GATA-3 is expressed in triple negative breast cancer and is more sensitive than the previously described markers gross cystic disease fluid protein 15 (GCDFP-15) and mammaglobin (MAM) [10, 11] . Since the nature of malignant effusions cannot be determined with certainty on morphologic examination alone, the need for more sensitive and specific markers still exists. Utilizing micro-arrays constructed from cell blocks we attempt to compare the performance of GATA-3 to MAM and GCDFP-15 in the diagnosis of breast carcinoma in serous effusions.
Materials and methods
Following Institutional Review Board approval with waiver of consent at Case Western Reserve University/University Hospitals Cleveland Medical Center, a total of 27 cases of serous effusions positive for breast cancer were retrieved from the archives through a computer system search. Hematoxylin and Eosin stained slides were evaluated for adequate cellularity. Selected cases comprised (23 ductal carcinomas, 2 lobular carcinomas, 1 mixed ductal and lobular carcinoma and 1 mucinous carcinoma). Cell-block microarrays (CMA) were constructed with three cores from each cell block using a 1 mm core needle. Immunohistochemical staining was performed on the TMA for GATA-3, MAM, GCDFP-15, ER and progesterone receptor (PR) ( Table 1) . Briefly, unstained 4 µm-sections were prepared from paraffin blocks and baked for 30 min at 60°C in a Boekel Lab oven. The slides were then processed using a Bond Automated Immunostainer (Leica) or a BenchMark Ultra (Ventana). The slides were deparaffinized; antigen retrieved, incubated in primary antibody and subsequently counterstained onboard the automated instruments.
Immunostained micro-array slides were examined and reactivity was scored as follows: staining intensity score (SIS) (0 = negative, 1 = weak, 2 = strong), and percentage of positive cells (PPC): (0 = 0 %, 1 = 1-25 %, 2 = 26-50 %, 3 = 51-75 %, and 4 = 76-100 %). Positivity was defined as reactivity in 1 % or more of malignant cells. Statistical analysis using two ways Chi Square, one-way ANOVA and multiple regression was performed on Excel 2016.
Results
The results are summarized in Tables 2-5. All 27 cases were well represented in the CMA sections. Twenty-five cases were pleural and two cases were peritoneal.
GATA-3, ER and PR showed nuclear positivity in reactive cases while MAM and GCDFP-15 showed a cytoplasmic pattern of expression (Figures 1 and 2 ).
Sensitivity
Out of the 27 cases studied, GATA-3, MAM and GCDFP-15 were positive in 24, 14 and 10 cases, respectively. The calculated sensitivity of GATA-3 for breast cancer of 88.8 % was significantly higher (X2 = 15.9, p = 0.00034) than that of MAM (51.8 %) and GCDFP-15 (37.0 %).
Percentage of positive cells score
Of the 24 GATA-3 positive cases, 15 (62.5 %) had a PPC score of 4/4, four (16.6 %) had PPC score of 3/4, one Antigen retrieval was performed with Cell Conditioning 1 (Ventana), a tris-based buffer with a slightly basic pH solution at 95°C. Table 2 : Immunohistochemical marker analysis in breast cancer in effusions (n = 27).
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Stain intensity score
For GATA-3, 20 (83.3 %) cases showed a staining intensity score of 2/2 and four (16.6 %) scored 1/2. For MAM, 13 (92.8 %) had staining intensity score of 2/2 and one (7.2 %) scored 1/2. For GCDFP-15, five (50 %) cases showed a staining intensity score of 2/2 and five (50 %) showed a staining intensity score of 1/2. One-way ANOVA analysis showed that the average staining score of all 27 cases was significantly higher (p = 0.0000002) in GATA-3 (1.6/2), compared to MAM (1.0/2) and GCDFP-15 (0.6/2).
The association between GATA-3, MAM and GCDFP-15 and ER expression The association between GATA-3, MAM and GCDFP-15 intensity of stain score and the percentage of positive cell score on one hand and ER intensity of stain score and 
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PPCS, percentage of positive cells score; MAM, mammaglobin; GCDFP-15, gross cystic disease fluid protein 15; ER, estrogen receptor; PR, progesterone receptor; no. + , number positive. Table 4 : Cross reactivity between GATA-3, MAM, GCDFP-15, ER and PR in breast cancer in effusions (number of positive cases). 
Discussion
GATA-3 is thought of as a defining marker of luminal breast cancer, which accounts for 70 % of breast carcinomas. ER-α and GATA-3 are often co-expressed, and GATA-3 is required for estradiol stimulation of cell cycle progression in breast carcinoma through direct positive regulation of ER-α. At the same time, ER-α is engaged in a positive cross-regulatory loop with GATA-3 as it also directly stimulates the transcription factor GATA-3, indicating that GATA-3 in association with ER can regulate critical genes in hormone-responsive breast cancer with statistically significant correlation between GATA-3 and ER expression [4, 7, 13, 14] . GATA-3 has been developed as an immunohistochemical marker for breast and urothelial carcinomas for use in routine diagnostic pathology practice [8, 15] . Although breast cancer is common, MAM and GCDFP-15 lack the desired sensitivity while ER and PR serve as prognostic markers with only adjunctive diagnostic utility, especially in the setting of a high-grade triple negative metastatic breast cancer. Using CMA our study demonstrates that GATA-3 is far more sensitive than GCDFP-15 and MAM with respective values of 88.8 %, 51.8 % and 37.0 %. Our results are comparable to a study by Shield et al. in which they reported sensitivity of GATA-3, MAM and GCDFP-15 to be 90 %, 57 % and 33 % respectively in serous effusions [16] . Braxton et al. who investigated breast cancer in cytology specimens reported sensitivity of GATA-3, MAM and GCDFP-15 to be 86 %, 26 % and 14 % respectively [17] . Their cohort included a higher number of ER negative carcinomas than our study and Shield et al. Another study performed on cell blocks showed sensitivity for GATA-3, MAM and GCDFP-15 to be 93.5 %, 22.4 % and 5.2 % respectively [18] . Surprisingly, GCDFP-15 performed much better in tissue specimens of primary and metastatic carcinomas staining 54.4 % of ductal carcinomas, 48.3 % of lobular carcinomas, and 81 % of apocrine mammary carcinomas [19] . When studied in ER negative carcinomas, Liu et al. reported a sensitivity of 15 % [20] compared to our 50 % in ER negative carcinomas. Huo et al. reported the sensitivity of GCDFP-15 in triple negative metastatic breast cancer to be 16% [12] . The same studies reported MAM sensitivity in tissue specimens to be 54 % in ductal carcinoma, 69 % in lobular carcinoma, and 36.4 % in apocrine mammary carcinomas with a sensitivity of 35 % in ER negative carcinoma and 32 % in triple negative carcinoma. Not surprisingly GATA-3 performance in tissue showed a sensitivity of over 90 % for breast carcinomas. More critically GATA-3 stained upto 69 % of ER negative breast cancer cases and 44 % of triple negative cases [12, 20] . In the setting of serous effusions in which material is limited and a sensitive easy to read marker is needed, our study and others have shown that GATA-3 is a sensitive and superior marker for breast differentiation when compared to MAM and GCDFP-15. It also performs superiorly in the setting of ER negative and triple negative breast carcinomas in which ER and PR cannot be used as adjunctive markers. Our study found that GATA-3 sensitivity in ER negative breast cancer cases to be 62.5 % compared to 42.8 % and 50 % for MAM and GCDFP-15 respectively; however, this needs to be interpreted cautiously due to the small number of ER negative cases in our cohort. The challenge with GATA-3 is its lack of tissue specificity as it can be expressed in urothelial carcinomas, pulmonary carcinomas, mesotheliomas, salivary gland tumors, and all skin adnexal tumors [5, 6, 8, 15, 17] . In the right morphologic and clinical setting GATA-3 has proven to be a useful marker in distinguishing breast cancer from other non-mammary carcinomas. We have also observed that GATA-3 may stain lymphocytes but not mesothelial cells which may obscure positive tumor cells especially in the setting of dispersed single carcinoma cells. Pathologists need to be aware of this pitfall when evaluating serous effusions with GATA-3.
Limitations of this study should be acknowledged: the sample size is only moderate with a relatively small number of ER negative cases. While we believe and have previously shown that micro-arrays constructed from cell blocks are adequate to asses various markers [9, 21] , the limited number of cells may have resulted in lower marker sensitivity. Overall, however, our results correlate well with previously published data.
In conclusion, GATA-3 is a useful and sensitive marker when compared to other existing markers of mammary differentiation (MAM and GCDFP-15). It can be particularly useful in the setting of ER-negative and triple negative breast cancer. We recommend using GATA-3 in a panel with other immunohistochemical markers when evaluating malignant pleural effusions.
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